Premium
The 1 year outcome of intravitreal dexamethasone implant for macular edema secondary to central retinal vein occlusion
Author(s) -
Kim H.W.,
Chung I.Y.,
Lee J.E.,
Kim K.
Publication year - 2016
Publication title -
acta ophthalmologica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.534
H-Index - 87
eISSN - 1755-3768
pISSN - 1755-375X
DOI - 10.1111/j.1755-3768.2016.0263
Subject(s) - medicine , macular edema , central retinal vein occlusion , dexamethasone , ophthalmology , intraocular pressure , implant , visual acuity , retinal vein , triamcinolone acetonide , bevacizumab , acetonide , surgery , chemotherapy
Purpose To evaluate 1‐year outcome of intravitreal dexamethasone implant in macular edema secondary to central retinal vein occlusion (CRVO). Methods A medical records was reviewed retrospectively for 22 patients (22 eyes) with macular edema secondary to central retinal vein occlusion. All of them were treated with intravitreal dexamethasone implant twice a year and followed up at least 1‐year from the first dexamethasone implant injection. The best‐corrected visual acuity (BCVA), central macular thickness (CMT) and intraocular pressure (IOP) was measured at every 2 months after the first injection. Adverse effects including cataract formation, elevation of IOP were analyzed. Results Mean age was 64.3 ± 9.5. Mean injection number was 2.4 ± 0.6 and interval between first and second injection was 22.0 ± 6.4 weeks. Additional treatments were performed with 11 patients (50%), bevacizumab in 9 and triamcinolone acetonide in 2. Mean BCVA (logMAR) was 0.79 ± 0.49 at pre‐injection and 0.72 ± 0.62 at 1 year. BCVA change was not significant (p = 0.638). But there was significant BCVA increase at 2, 4, 6 month after first injection (p < 0.001). The number of patients who improved in BCVA was 10 (45.5%) at 1 year. Mean CMT at baseline was 627.3 ± 149.7 μ m and 458.4 ± 139.0 μ m at 1 year, significant decrease compared to baseline (p < 0.001). In subgroup analysis, Hypertension (HTN) group showed significant improvement in BCVA and CMT compared to non‐HTN group (p = 0.044; BCVA, p = 0.005; CMT). Ischemic group represented significant decrease at CMT (p < 0.001). Elevated intraocular pressure was observed in 6 eyes (27.3%). Cataract formation was in 3 eyes (13.6%). Conclusions Intravitreal dexamethasone implant was effective in stabilizing visual acuity and reduction of macular edema in patients with macular edema secondary to central retinal vein occlusion.